600129 太极集团
已收盘 07-03 15:00:00
资讯
新帖
简况
太极集团(600129)股东太极集团有限公司质押400万股,占总股本0.73%
证券之星 · 07-01 18:28
太极集团(600129)股东太极集团有限公司质押400万股,占总股本0.73%
太极集团:提取工序搭载DCS自动控制系统
证券之星 · 06-29
太极集团:提取工序搭载DCS自动控制系统
太极集团:公司将紧密贴合市场需求加大藿香正气口服液的品牌推广与终端动销力度
证券之星 · 06-29
太极集团:公司将紧密贴合市场需求加大藿香正气口服液的品牌推广与终端动销力度
异动快报:太极集团(600129)6月29日10点54分触及涨停板
证券之星 · 06-29
异动快报:太极集团(600129)6月29日10点54分触及涨停板
太极集团:产品销量数据为生产厂向经销商发货的渠道销售数据
证券之星 · 06-24
太极集团:产品销量数据为生产厂向经销商发货的渠道销售数据
太极集团:公司累计完成12个中药材品种的GAP符合性延伸检查
证券之星 · 06-24
太极集团:公司累计完成12个中药材品种的GAP符合性延伸检查
太极集团:战略聚焦,创新驱动,打造中药特色领军企业
证券之星 · 06-22
太极集团:战略聚焦,创新驱动,打造中药特色领军企业
太极集团:公司聚焦主责主业,着力提质增效
证券之星 · 06-22
太极集团:公司聚焦主责主业,着力提质增效
太极集团:2025年在二级市场开展股份回购工作
证券之星 · 06-22
太极集团:2025年在二级市场开展股份回购工作
太极集团:公司目前生产经营正常
证券之星 · 06-22
太极集团:公司目前生产经营正常
太极集团:藿香正气口服液入选《埃博拉病毒病诊疗方案(2026年版)》
证券之星 · 06-22
太极集团:藿香正气口服液入选《埃博拉病毒病诊疗方案(2026年版)》
太极集团:公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份
证券之星 · 06-22
太极集团:公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份
太极集团:中药大模型具备中药知识提取与生成、中药垂直领域解决方案输出、中药产业一站式数字化服务三大功能
证券之星 · 06-22
太极集团:中药大模型具备中药知识提取与生成、中药垂直领域解决方案输出、中药产业一站式数字化服务三大功能
太极集团:已成功承接川渝两家核心中医院饮片代煎业务
证券之星 · 06-22
太极集团:已成功承接川渝两家核心中医院饮片代煎业务
太极集团:市值管理包括但不限于规范治理、提升价值创造力、提高信息披露质量、加强投资者关系管理、合理制定股东分红政策等
证券之星 · 06-22
太极集团:市值管理包括但不限于规范治理、提升价值创造力、提高信息披露质量、加强投资者关系管理、合理制定股东分红政策等
太极集团:公司为促进产品销售,对部分产品的经销商账期有阶段性的调整
证券之星 · 06-22
太极集团:公司为促进产品销售,对部分产品的经销商账期有阶段性的调整
太极集团:持续推进工业营销转型
证券之星 · 06-22
太极集团:持续推进工业营销转型
太极集团最新公告:盐酸肾上腺素注射液通过仿制药一致性评价
证券之星 · 06-10
太极集团最新公告:盐酸肾上腺素注射液通过仿制药一致性评价
太极集团(600129.SH)子公司盐酸托莫西汀胶囊获得药品注册证书
智通财经 · 06-10
太极集团(600129.SH)子公司盐酸托莫西汀胶囊获得药品注册证书
每周股票复盘:太极集团(600129)将参加乡村振兴业绩说明会
证券之星 · 06-07
每周股票复盘:太极集团(600129)将参加乡村振兴业绩说明会
加载更多
公司概况
公司名称:
重庆太极实业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1997-11-18
主营业务:
重庆太极实业(集团)股份有限公司的主营业务是中、西成药的生产和销售。公司的主要产品是藿香正气口服液、急支糖浆、通天口服液、盐酸吗啡缓释片、洛芬待因缓释片、注射用头孢唑肟钠、氯化钠注射液、复方对乙酰氨基酚片(Ⅱ)、复方甘草片、鼻窦炎口服液、小金片。公司获国家科技进步奖2项、省级科技奖13项,省级优秀奖10余项、中国专利金奖3项、中国专利优秀奖1项。
发行价格:
7.00
{"stockData":{"symbol":"600129","market":"SH","secType":"STK","nameCN":"太极集团","latestPrice":14.09,"timestamp":1783062000000,"preClose":13.6,"halted":0,"volume":20830285,"delay":0,"changeRate":0.036,"floatShares":551000000,"shares":551000000,"eps":0.2025,"marketStatus":"已收盘","change":0.49,"latestTime":"07-03 15:00:00","open":13.66,"high":14.16,"low":13.66,"amount":289000000,"amplitude":0.0368,"askPrice":14.1,"askSize":1467,"bidPrice":14.09,"bidSize":2315,"shortable":0,"etf":0,"ttmEps":0.2025,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":13.6,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":14.96,"lowLimit":12.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":551418185,"isCdr":false,"pbRate":2.18,"roa":"--","peRate":69.580247,"roe":"1.86%","epsLYR":0.22,"committee":0.336501,"marketValue":7769000000,"turnoverRate":0.0378,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-06。","floatMarketCap":7769000000},"requestUrl":"/m/hq/s/600129/","defaultTab":"news","newsList":[{"id":"2648591512","title":"太极集团(600129)股东太极集团有限公司质押400万股,占总股本0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648591512","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648591512?lang=zh_cn&edition=full","pubTime":"2026-07-01 18:28","pubTimestamp":1782901710,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团7月1日公开信息显示,股东太极集团有限公司向上海浦东发展银行股份有限公司重庆分行合计质押400.0万股,占总股本0.73%。质押详情见下表:截止本公告日,股东太极集团有限公司已累计质押股份2834.0万股,占其持股总数的18.43%。太极集团主营业务:主要从事中、西成药的生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100036155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","600129","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647243233","title":"太极集团:提取工序搭载DCS自动控制系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2647243233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647243233?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:18","pubTimestamp":1782721111,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团06月29日在投资者关系平台上答复投资者关心的问题。或者萃取工艺改进?公司将持续严守GMP合规生产标准,持续导入绿色低碳、节能高效的先进新型工艺技术,迭代优化提取生产工艺,稳步提升中药材有效成分提取收率与整体生产线运营效能,不断夯实核心生产制造竞争力,保障经营效益稳定提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900023391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302324","title":"太极集团:公司将紧密贴合市场需求加大藿香正气口服液的品牌推广与终端动销力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302324","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647302324?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:18","pubTimestamp":1782721107,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问:今年夏天预计很热,请问公司如何预测今年藿香正气液的销售情况?相比去年呢?去库存情况目前如何?近期我在你们重庆大本营的自有桐君阁药房还看到了2023年生产的藿香正气液。太极集团回复:您好!感谢对公司的关注。公司将紧密贴合市场需求加大藿香正气口服液的品牌推广与终端动销力度,多渠道开展防暑主题活动、门店专项促销及企业团购,提升终端销量。藿香正气口服液的保质期为36个月,药店售卖的该产品在有效期内。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900023384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0113","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347901","title":"异动快报:太极集团(600129)6月29日10点54分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347901?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:55","pubTimestamp":1782701722,"startTime":"0","endTime":"0","summary":"证券之星6月29日盘中消息,10点54分太极集团(600129)触及涨停板。其所属行业中药目前上涨。领涨股为康缘药业。该股为健康中国,医药,中药概念热股,当日健康中国概念上涨4.78%,医药概念上涨4.44%,中药概念上涨3.49%。6月26日的资金流向数据方面,主力资金净流出1065.36万元,占总成交额10.38%,游资资金净流出76.87万元,占总成交额0.75%,散户资金净流入1142.23万元,占总成交额11.13%。近5日资金流向一览见下表:太极集团主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900010334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0113","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891952","title":"太极集团:产品销量数据为生产厂向经销商发货的渠道销售数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891952?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:57","pubTimestamp":1782295045,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司现在能否获取终端动销实时数据?2025年藿香正气口服液终端动销多少支?是否追评2023年动销数量?(多少支)太极集团回复:您好!感谢对公司的关注。公司在2025年年度报告中对藿香正气口服液等主要产品的产销量情况进行了披露,产品销量数据为生产厂向经销商发货的渠道销售数据。因终端实动销数据来源于各连锁药店、社会单体药店及个体诊所等,数据来源分散、口径不统一,为实时动态数据。敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","600129","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891688","title":"太极集团:公司累计完成12个中药材品种的GAP符合性延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891688?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:57","pubTimestamp":1782295044,"startTime":"0","endTime":"0","summary":"截止目前,公司累计完成12个中药材品种的GAP符合性延伸检查,对应标准化基地总面积约3万亩。新版中药材GAP规范采用延伸检查制,经官方公告通过符合性延伸检查的品种药材,中药生产企业经质量审计,评估确认满足GAP规范要求,可直接采购使用;尚未纳入公告名录的药材,中药生产企业完成内部自评,或第三方评估,且确认满足GAP规范全部要求后,可按GAP药材管理、使用并规范标识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645102540","title":"太极集团:战略聚焦,创新驱动,打造中药特色领军企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2645102540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645102540?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:12","pubTimestamp":1782123148,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:6.3万多散户已经开始抵制太极的产品了,难道公司没有任何反思?太极集团回复:您好!感谢对公司的关注。公司聚焦主责主业,以“战略聚焦,创新驱动,打造中药特色领军企业”的战略目标,充分挖掘疗效确切、百姓认可、独家优势、经典普药等产品资源,系统规划产品梯队,着力营销创新、科技创新、学术赋能、品牌破圈,数据驱动,强化内部治理,降本增效提升业绩,履行央企担当,敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200028062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","600129","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025233","title":"太极集团:公司聚焦主责主业,着力提质增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025233?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:12","pubTimestamp":1782123139,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:天天作秀,搞所谓的公益互动,然后弄点新闻出来,貌似做了很多事的样子,请问作为央企,就是这么履行社会责任的么?太极集团回复:您好!感谢对公司的关注。公司聚焦主责主业,着力提质增效,严控经营风险,以稳定的经营业绩创造内在价值,敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200028044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600129","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025281","title":"太极集团:2025年在二级市场开展股份回购工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025281?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:12","pubTimestamp":1782123138,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:太极集团作为央企控股上市公司,公司股价从高位60多元一路下跌到目前不足13元,跌幅巨大,公司是否有市值维护部门和相关工作人员,是否有开展市值维护工作,对于市值维护是否有相应考核机制?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200028041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645251970","title":"太极集团:公司目前生产经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2645251970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645251970?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:09","pubTimestamp":1782122947,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团06月22日在投资者关系平台上答复投资者关心的问题。感谢对公司的关注。公司目前生产经营正常。股票价格受宏观经济、行业周期、市场资金偏好等多重外部因素影响,敬请投资者理性投资、注意投资风险。公司立足医药主业,围绕规范治理、聚焦主业、科技创新、精益运营等方向,不断夯实发展基础、提升经营质效、增强价值创造能力,加快品牌建设,履行央企担当,敬请关注公司发布的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0113","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645251600","title":"太极集团:藿香正气口服液入选《埃博拉病毒病诊疗方案(2026年版)》","url":"https://stock-news.laohu8.com/highlight/detail?id=2645251600","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645251600?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:09","pubTimestamp":1782122946,"startTime":"0","endTime":"0","summary":"投资者提问:2017年公司推出的“藿香正气口服液百万真实世界案例研究”项目进展如何?现在相关藿香正气口服液的研究项目有哪些?同时,藿香正气口服液入选《埃博拉病毒病诊疗方案》,进入《小儿胃肠型感冒中医药诊治及疗效评价指南》《诺如病毒胃肠炎诊疗方案》《中西医联合防治儿童流感临床应用指南》《中国临床肿瘤学会抗肿瘤治疗相关恶心呕吐预防和治疗指南2025》,相关情况敬请关注公司发布的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600129","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645202583","title":"太极集团:公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645202583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645202583?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:57","pubTimestamp":1782122231,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:国药集团控股比例是否已突破30%?是上次回购被动突破的么?太极集团回复:您好!感谢对公司的关注。公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份,敬请详见公司披露的定期报告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0175","BK0113","BK0188","BK0010","BK0239","600056","BK0250","BK0082","600129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025864","title":"太极集团:中药大模型具备中药知识提取与生成、中药垂直领域解决方案输出、中药产业一站式数字化服务三大功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025864","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025864?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:57","pubTimestamp":1782122231,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问“本草智库”大模型,公司是否已经应用了,有哪些应用场景?确定哪些收益?太极集团回复:您好!感谢对公司的关注。中药大模型模型具备中药知识提取与生成、中药垂直领域解决方案输出、中药产业一站式数字化服务三大功能。公司为“本草智库”大模型联合开发单位,将继续与中药领域的专家学者紧密合作,强化科技创新,不断优化和完善本草智库大模型,推动中药产业的数字化及高质量发展。相关情况敬请关注公司发布公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025835","title":"太极集团:已成功承接川渝两家核心中医院饮片代煎业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025835","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025835?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:57","pubTimestamp":1782122226,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:公司现在的智慧煎配+智能配送柜的模式是否可直接服务终端病人?现在业务进展如何?是否有计划推广全国?太极集团回复:您好!感谢对公司的关注。公司现有四川、重庆2个现代化智慧煎配中心,已成功承接川渝两家核心中医院饮片代煎业务,处方量突破3000张/天。相关情况敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","BK0239","600129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025897","title":"太极集团:市值管理包括但不限于规范治理、提升价值创造力、提高信息披露质量、加强投资者关系管理、合理制定股东分红政策等","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025897?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:54","pubTimestamp":1782122056,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请你问公司有市值管理的概念么?有具体的措施么?看看去年的增持,真是搞笑!堂堂央企,竟然把市值管理做成这样???太极集团回复:您好!感谢对公司的关注。市值管理包括但不限于规范治理、提升价值创造力、提高信息披露质量、加强投资者关系管理、合理制定股东分红政策等,公司将根据市场、相关制度要求及投资者需求等各方面统筹考虑,敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0113","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025895","title":"太极集团:公司为促进产品销售,对部分产品的经销商账期有阶段性的调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645025895?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:54","pubTimestamp":1782122055,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问一季度经营性现金流为-4亿元,同时应收数额明显增加的原因有哪些?是否跟结算模式转换有关?是否与新开发非西南地区的终端有关系?能否尽量量化说名字原因?太极集团回复:您好!感谢对公司的关注。公司为促进产品销售,对部分产品的经销商账期有阶段性的调整。敬请关注公司发布的公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0113","600129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645838025","title":"太极集团:持续推进工业营销转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2645838025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645838025?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:54","pubTimestamp":1782122047,"startTime":"0","endTime":"0","summary":"证券之星消息,太极集团06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:从2025年一季报看到非西南地区营收有明显增长?请问公司哪些规划和措施支持全国性的放量增长?西南大本营与华东为何持续下滑,有哪些措施扭转下滑趋势?感谢对公司的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642433441","title":"太极集团最新公告:盐酸肾上腺素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2642433441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642433441?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:50","pubTimestamp":1781081452,"startTime":"0","endTime":"0","summary":"太极集团(600129.SH)公告称,公司控股子公司西南药业的盐酸肾上腺素注射液通过仿制药质量和疗效一致性评价。该药品主要用于支气管痉挛所致严重呼吸困难、过敏性休克及心脏骤停抢救。2025年该药品在中国市场销售总额为2.37亿元,西南药业累计研发投入688.1万元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600129","BK0239","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642446860","title":"太极集团(600129.SH)子公司盐酸托莫西汀胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446860","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642446860?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:41","pubTimestamp":1781077273,"startTime":"0","endTime":"0","summary":"智通财经APP讯,太极集团(600129.SH)发布公告,近日,公司控股子公司西南药业股份有限公司收到国家药品监督管理局颁发的盐酸托莫西汀胶囊的《药品注册证书》。该药品适用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"太极集团(600129.SH)子公司盐酸托莫西汀胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0113","600129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127297","title":"每周股票复盘:太极集团(600129)将参加乡村振兴业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127297?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:56","pubTimestamp":1780772171,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,太极集团报收于13.76元,较上周的14.33元下跌3.98%。本周,太极集团6月2日盘中最高价报14.85元。本周关注点公司公告汇总:太极集团将参加2025年度沪市主板乡村振兴集体业绩说明会公司公告汇总太极集团关于参加2025年度沪市主板惠民促消费之乡村振兴集体业绩说明会的公告重庆太极实业(集团)股份有限公司将于2026年6月10日14:00—17:00参加由上海证券交易所举办的2025年度沪市主板惠民促消费之乡村振兴集体业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600129","BK0113"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783157264263,"stockEarnings":[{"period":"1week","weight":0.188},{"period":"1month","weight":-0.0147},{"period":"3month","weight":-0.1445},{"period":"6month","weight":-0.2194},{"period":"1year","weight":-0.344},{"period":"ytd","weight":-0.2194}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆太极实业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63770人(较上一季度增加0.41%)","perCapita":"8646股","listingDate":"1997-11-18","address":"重庆市涪陵区太极大道1号","registeredCapital":"55141万元","survey":" 重庆太极实业(集团)股份有限公司的主营业务是中、西成药的生产和销售。公司的主要产品是藿香正气口服液、急支糖浆、通天口服液、盐酸吗啡缓释片、洛芬待因缓释片、注射用头孢唑肟钠、氯化钠注射液、复方对乙酰氨基酚片(Ⅱ)、复方甘草片、鼻窦炎口服液、小金片。公司获国家科技进步奖2项、省级科技奖13项,省级优秀奖10余项、中国专利金奖3项、中国专利优秀奖1项。","listedPrice":7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"太极集团(600129)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供太极集团(600129)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"太极集团,600129,太极集团股票,太极集团股票老虎,太极集团股票老虎国际,太极集团行情,太极集团股票行情,太极集团股价,太极集团股市,太极集团股票价格,太极集团股票交易,太极集团股票购买,太极集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"太极集团(600129)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供太极集团(600129)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}